Clinical trials for Undifferentiated connective tissue disease

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44335 clinical trials with a EudraCT protocol, of which 7366 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (14)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

14 result(s) found for: Undifferentiated connective tissue disease. Displaying page 1 of 1.

EudraCT Number: 2020-002366-13

Sponsor Protocol Number: IB2020-02

Start Date*: 2021-12-20

Sponsor Name:Institut Bergonié

Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas

Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10039494	Sarcoma NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-003145-17

Sponsor Protocol Number: TH-CR-406/SARC021

Start Date*: 2012-02-28

Sponsor Name:Threshold Pharmaceuticals, Inc.

Full Title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue S...

Medical condition: Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041299	Soft tissue sarcomas	HLGT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed) DE (Completed) HU (Completed) PL (Prematurely Ended) BE (Completed) IT (Completed) AT (Prematurely Ended) DK (Prematurely Ended)

Trial results: View results

EudraCT Number: 2016-002243-42

Sponsor Protocol Number: GCT1021-01

Start Date*: 2016-10-25

Sponsor Name:Genmab A/S

Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors.

Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014742	Endometrial neoplasms malignant	HLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008342	Cervix carcinoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023774	Large cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002240	Anaplastic thyroid cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025650	Malignant melanoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039491	Sarcoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014733	Endometrial cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2020-004163-12

Sponsor Protocol Number: 2020-012-GLOB1

Start Date*: 2021-11-04

Sponsor Name:Hutchison MediPharma Limited

Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors

Medical condition: Advanced Solid Tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061451	Colorectal cancer	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10052399	Neuroendocrine tumour	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059514	Small cell lung cancer metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10017758	Gastric cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075333	Soft tissue sarcoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) FR (Completed)

Trial results: (No results available)

EudraCT Number: 2006-001861-40

Sponsor Protocol Number: BRTA-0100-015 (EORTC 62061)

Start Date*: 2006-09-21

Sponsor Name:SYSTEMS MEDICINE, LLC

Full Title: Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma

Medical condition: Advanced or metastatic soft tissue sarcoma.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10041299	Soft tissue sarcomas	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed)

Trial results: (No results available)

EudraCT Number: 2021-003762-13

Sponsor Protocol Number: NIO-0002

Start Date*: 2022-07-05

Sponsor Name: Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie – Państwowy Instytut Badawczy (NIO-PIB)

Full Title: PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH METASTASES (ANNA-SARC)

Medical condition: soft tissue sarcomas

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075333	Soft tissue sarcoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2005-004272-20

Sponsor Protocol Number: E7389-E044-207

Start Date*: 2006-10-23

Sponsor Name:Eisai Limited

Full Title: Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27)

Medical condition: Advanced and/or metastatic soft tissue sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10041299	Soft tissue sarcomas	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) DE (Completed) DK (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2008-008922-55

Sponsor Protocol Number: GEIS20

Start Date*: 2009-06-04

Sponsor Name:Grupo Español de Investigación en Sarcomas

Full Title: ENSAYO FASE II ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA vs TRABECTEDINA Y DOXORRUBICINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMA DE PARTES BLANDAS AVANZADOS NO OPERABLES...

Medical condition: Sarcoma de partes blandas avanzados no operables y/o metastásicos

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9		10041299	Soft tissue sarcomas	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2021-001256-34

Sponsor Protocol Number: CAIN457X12301

Start Date*: 2022-02-07

Sponsor Name:Novartis Pharma AG

Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in pa...

Medical condition: Peripheral Spondyloarthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	24.1	10028395 - Musculoskeletal and connective tissue disorders	10085753	Peripheral spondyloarthritis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2020-005703-39

Sponsor Protocol Number: IB2020-05

Start Date*: 2021-07-27

Sponsor Name:Institut Bergonié

Full Title: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma.

Medical condition: soft-tissue sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10039494	Sarcoma NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2012-001399-12

Sponsor Protocol Number: MORAb-004-203-STS

Start Date*: 2014-01-02

Sponsor Name:Morphotek Inc.

Full Title: A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma

Medical condition: Metastatic Soft Tissue Sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041299	Soft tissue sarcomas	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) NL (Prematurely Ended)

Trial results: View results

EudraCT Number: 2010-023484-17

Sponsor Protocol Number: 2010-023484-17

Start Date*: 2011-06-11

Sponsor Name:ITALIAN SARCOMA GROUP

Full Title: LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01)

Medical condition: High risk localized soft tissue sarcomas typical of the adult

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10041299		HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed) ES (Ongoing) PL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2019-004359-35

Sponsor Protocol Number: ICEA2020.1

Start Date*: 2020-10-23

Sponsor Name:Leiden University Medical Center

Full Title: Induction of Cure in Early Arthritis

Medical condition: early unclassified arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10028395 - Musculoskeletal and connective tissue disorders	10062164	Seronegative arthritis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed)

Trial results: (No results available)

EudraCT Number: 2011-003745-18

Sponsor Protocol Number: GISG-04

Start Date*: 2012-05-22

Sponsor Name:University of Heidelberg

Full Title: A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF PREOPERATIVE THERAPY WITH PAZOPANIB (VOTRIENT®) IN HIGH-RISK SOFT TISSUE SARCOMA

Medical condition: High-risk soft tissue sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041298	Soft tissue sarcomas histology unspecified	HLT
	15.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041299	Soft tissue sarcomas	HLGT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024628	Liposarcomas malignant	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024190	Leiomyosarcomas	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023285	Kaposi's sarcomas	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001883	Alveolar soft part sarcomas	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025224	Lymphangiosarcomas	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039023	Rhabdomyosarcomas	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016634	Fibrosarcomas malignant	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029273	Neurofibrosarcomas	HLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015100	Epithelioid sarcomas	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Fri May 09 20:42:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA